R1	Has_value Arg1:T7 Arg2:T8	
R2	Has_value Arg1:T10 Arg2:T11	
R3	AND Arg1:T9 Arg2:T10	
R4	AND Arg1:T2 Arg2:T3	
*	OR T2 T9
R5	Has_temporal Arg1:T4 Arg2:T15	
R6	Has_qualifier Arg1:T16 Arg2:T18	
R7	Has_negation Arg1:T16 Arg2:T17	
R8	Subsumes Arg1:T28 Arg2:T29	
R9	Subsumes Arg1:T26 Arg2:T27	
R10	Has_multiplier Arg1:T21 Arg2:T20	
R11	Has_qualifier Arg1:T20 Arg2:T19	
R12	Has_qualifier Arg1:T23 Arg2:T22	
R13	Has_temporal Arg1:T23 Arg2:T24	
R14	Has_value Arg1:T25 Arg2:T26	
*	OR T16 T21 T23
R15	Has_value Arg1:T31 Arg2:T32	
R16	Has_index Arg1:T5 Arg2:T6	
R17	Has_temporal Arg1:T2 Arg2:T5	
R18	AND Arg1:T2 Arg2:T7	
R19	Has_value Arg1:T25 Arg2:T28	
T1	Informed_consent 0 110	Patients are able to provide signed and dated written informed consent prior to any study specific procedures.
T2	Person 112 117	Women
T3	Condition 122 137	post-menopausal
T4	Condition 371 375	T2DM
T5	Temporal 147 190	as at least 1 year post cessation of menses
T6	Reference_point 171 190	cessation of menses
T7	Person 196 200	aged
T8	Value 201 220	= 45 and = 70 years
T9	Person 222 227	Males
T10	Person 232 236	aged
T11	Value 237 262	= 40 years and = 70 years
T12	Non-representable 264 341	Patients should have suitable veins for cannulation or repeated venipuncture.
T15	Temporal 376 406	for at least the last 6 months
T16	Procedure 434 462	anti-diabetic drug treatment
T17	Negation 425 427	no
T18	Qualifier 428 433	other
T19	Qualifier 470 476	stable
T20	Multiplier 477 503	maximum 3000 mg daily dose
T21	Drug 504 513	metformin
T22	Qualifier 534 545	stable dose
T23	Drug 551 566	DPPIV inhibitor
T24	Temporal 577 607	for at least the last 3 months
T25	Measurement 610 622	HbA1c levels
T26	Value 623 628	=6.0%
T27	Value 630 642	=42 mmol/mol
T28	Value 648 653	=9.0%
T29	Value 655 666	75 mmol/mol
T31	Measurement 677 698	body mass index (BMI)
T32	Value 699 709	= 35 kg/m2
